about
Axonal transport disruption in peripheral nerve disease: From Jack's discoveries as a resident to recent contributionsPeripheral neuropathy: clinical and electrophysiological considerations.Endophilin mutations block clathrin-mediated endocytosis but not neurotransmitter releaseThe C9orf72 repeat expansion disrupts nucleocytoplasmic transport.The ALS gene FUS regulates synaptic transmission at the Drosophila neuromuscular junction.Evaluation and construction of diagnostic criteria for inclusion body myositisSynaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathyA Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43.Neuropeptide delivery to synapses by long-range vesicle circulation and sporadic capture.CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.The p150(Glued) CAP-Gly domain regulates initiation of retrograde transport at synaptic termini.Spectrum of Muscle Histopathologic Findings in Forty-Two Scleroderma Patients With Weakness.Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis.Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease.Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune DiseasesNucleocytoplasmic transport in C9orf72-mediated ALS/FTD.Top3β is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation.Tdp-43 cryptic exons are highly variable between cell types.WIDE AWAKE mediates the circadian timing of sleep onset.Novel therapeutic approaches for inclusion body myositis.Sciatic nerve tumor and tumor-like lesions - uncommon pathologies.FIG4 regulates lysosome membrane homeostasis independent of phosphatase function.A TRPV channel in Drosophila motor neurons regulates presynaptic resting Ca2+ levels, synapse growth, and synaptic transmission.Mutant Huntingtin Disrupts the Nuclear Pore Complex.Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients.Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy.Statin-Induced Anti-HMGCR-Associated Myopathy.A Case of Morvan Syndrome Mimicking Amyotrophic Lateral Sclerosis With Frontotemporal Dementia.Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.Drosophila models of neurologic disease.Whole-body MR neurography: Prospective feasibility study in polyneuropathy and Charcot-Marie-Tooth disease.TRPV4 disrupts mitochondrial transport and causes axonal degeneration via a CaMKII-dependent elevation of intracellular Ca2
P50
Q26865470-B0E2E52A-005A-421C-96E7-C13D59111CDAQ27693190-628E4C0A-1E31-44CC-87CF-D2AF002EFD2AQ28214771-3F7360F0-8868-4966-9437-86948A9C9D9EQ29871482-DFE80DAA-9136-4FAF-8C7F-816D34AE7D1EQ33784500-A8E62216-3509-47EE-9EFF-4808E173CEBBQ34043780-8FD1BCBC-62FC-442F-8E0A-569EA9DECB6BQ34146828-AC70015F-20EA-4B66-9CC6-81513A8275E9Q34882752-FF3DB059-95EC-4F30-AF11-0613D89D949EQ35803998-2E1C2E44-64B8-41DA-ACA7-148406FE3A70Q35891892-80F9A68C-C4C5-469C-A79F-7DE8AFBC21AFQ35965342-F5C0723B-C841-4708-AF5B-35B54BC05767Q36087017-6AE99FF6-ED17-4CB3-9628-8EB10E215194Q36232194-8F61C856-E68D-4B8C-BA60-219481DE73DCQ36364785-6DA282FB-6622-4106-A3A7-B43F4C9702BBQ36434543-846FD989-5674-4044-9559-33661FFF21FFQ36953554-5F64A80F-DB2D-4CF2-A2EA-DD8AD562216CQ37028365-F720E288-EA53-447B-9B52-2368BB53EB9EQ37368860-6720E3CC-BBCA-49DE-8C73-9949548BDED3Q37621005-35AE5026-4A57-46E5-82EA-3587F6E12A38Q37696487-A7694431-F6ED-4748-A935-86F1A5ECFA3DQ37786521-4FBB4DB7-9662-4550-9003-927103AC5118Q37992843-27F2722E-F5B6-4DDF-BF74-96CBCCCD63AAQ38270487-F9DC3AE5-9C87-41BA-92CE-76DA54A657E8Q38446556-525A8568-3B91-4E50-87A6-4F5684F05F06Q38734025-C72EB799-B301-4267-81F1-BFF5C353E6D9Q40298726-EFD06E65-4A60-4BF4-8505-BD07F4B96BACQ42014200-2A5CED33-1E5A-43AF-8063-1387797CE1ADQ42255031-1E352482-6C94-47DB-9834-C834A6728FC7Q47427061-DE470704-9854-4DEA-86D3-8597F7BD1E24Q48344148-DABA42CA-80D4-4744-8851-DDE0E2EBA363Q52838660-65CCC673-D555-40FC-8556-D90F5B05CAC4Q53112002-CBD40D4A-7D66-4855-BAAF-6DC383D4CF7FQ96022636-3166EE5E-3734-4B85-8CE4-23BB34926B60
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thomas E Lloyd
@nl
Thomas E Lloyd
@sl
Thomas E. Lloyd
@en
Thomas E. Lloyd
@es
type
label
Thomas E Lloyd
@nl
Thomas E Lloyd
@sl
Thomas E. Lloyd
@en
Thomas E. Lloyd
@es
prefLabel
Thomas E Lloyd
@nl
Thomas E Lloyd
@sl
Thomas E. Lloyd
@en
Thomas E. Lloyd
@es
P106
P1153
36797856700
P21
P31
P496
0000-0003-4756-3700